PEG-PCL block copolymers from PolySciTech used in development of treatment of ovarian cancer

 

Ovarian cancer is a common and fatal disease. A woman's lifetime risk of developing ovarian cancer is 1 in 78. A woman's lifetime risk of dying from invasive ovarian cancer is 1 in 108. Researchers at Sungkyunkwan University School of Medicine and Chungbuk National University utilized mPEG-PCL (Cat# AK073) from PolySciTech division of Akina, Inc. (www.polyscitech.com) to create micelles loaded with fenbendazole and rapamycin for treatment of ovarian cancer. This research holds promise to improve therapy against this deadly disease. Read more: Shin, Yu Been, Ju-Yeon Choi, Dae Hwan Shin, and Jeong-Won Lee. "Anticancer Evaluation of Methoxy Poly (Ethylene Glycol)-b-Poly (Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer." International Journal of Nanomedicine (2023): 2209-2223. https://www.tandfonline.com/doi/abs/10.2147/IJN.S394712

“Abstract: We aimed to inhibit ovarian cancer (OC) development by interfering with microtubule polymerization and inhibiting mTOR signaling. To achieve this, previously developed micelles containing fenbendazole and rapamycin were applied. Herein, we prepared micelles for drug delivery using fenbendazole and rapamycin at a 1:2 molar ratio and methoxy poly(ethylene glycol)-b-poly(caprolactone)(mPEG-b-PCL) via freeze-drying. We revealed their long-term storage capacity of up to 120 days. Furthermore, a cytotoxicity test was performed on the OC cell line HeyA8, and an orthotopic model was established for evaluating in vivo antitumor efficacy. Fenbendazole/rapamycin-loaded mPEG-b-PCL micelle (M-FR) had an average particle size of 37.2 ± 1.10 nm, a zeta potential of −0.07 ± 0.09 mV, and a polydispersity index of 0.20 ± 0.02. Additionally, the average encapsulation efficiency of fenbendazole was 75.7 ± 4.61% and that of rapamycin was 98.0 ± 1.97%. In the clonogenic assay, M-FR was 6.9 times more effective than that free fenbendazole/rapamycin. The in vitro drug release profile showed slower release in the combination formulation than in the single formulation. There was no toxicity, and tumor growth was suppressed substantially by our formulation compared with that seen with the control. The findings of our study lay a foundation for using fenbendazole and rapamycin for OC treatment.”

Video: https://youtu.be/CUbXxnGHjOQ

Akina Inc. is now hiring both Staff Scientist and Laboratory Intern. See more here: http://akinainc.com/employment.php

Bulk, empty bottles from pandemic-era hand-sanitizer manufacturing and other excess inventory items are available for purchase from Akina, Inc. See more here: https://akinainc.com/polyscitech/YardSale/